Skip to content
A10521Assembly2025-2026 SessionSame asS10260

Expand Newborn Disease Screening

Official title

“Adds CLN2, MPS IVA, MPS VI, MPS VII and Fabry diseases to the newborn screening panel for New York state”

Sponsor Andrew HevesiAD-28+7 co-sponsorsAffects Health
Status
In Assembly Committee
Health
Impact
6/10
Moderate
Passage
33%

Bill progress

Step 2 of 7

In committee · Health

What's happening

This bill adds CLN2, MPS IVA, MPS VI, MPS VII, and Fabry diseases to New York's mandatory newborn screening.

Why it matters

  1. Early detection of rare, serious diseases. By adding CLN2, MPS IVA, MPS VI, MPS VII, and Fabry diseases to mandatory newborn screening, the bill ensures infants with these life-threatening, progressive genetic disorders can be identified before symptoms appear, allowing for earlier intervention.

  2. Potential for improved health outcomes and quality of life. Early diagnosis of these conditions enables timely access to treatments and specialized care, which can slow disease progression, reduce complications, and in some cases, prevent severe disability or premature death.

  3. Reduced burden on families and healthcare systems. Early screening may decrease the emotional, financial, and medical challenges faced by families, as well as reduce long-term healthcare costs associated with delayed diagnosis and advanced disease management.

  4. Supports health equity. Making these screenings mandatory ensures all newborns in New York, regardless of socioeconomic status or geographic location, are tested, helping to close gaps in access to life-saving early detection and care.

The daily · weekday mornings

Albany, before your first meeting.

Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.

Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.

Who cares

  • Families with Newborns

    Parents and guardians who may benefit from early detection and intervention for CLN2, MPS IVA, MPS VI, MPS VII, and Fabry diseases through expanded newborn screening.

  • Individuals with Rare Genetic Diseases

    Patients and advocacy groups for these specific rare diseases, who seek earlier diagnosis to improve treatment outcomes and quality of life.

  • Healthcare Providers and Hospitals

    Pediatricians, neonatologists, and hospital systems responsible for administering newborn screenings and providing follow-up care or referrals for positive results.

  • Public Health Agencies and Laboratories

    State and local health departments as well as public health laboratories tasked with implementing, managing, and funding the expanded screening programs.

Headline styles

Expand Newborn Disease Screening

Plain English, a few words. Used as the page title.

Sponsors

Primary sponsor
Andrew Hevesi

Assembly Member · Assembly District 28

Chair, Children and Families

History

  1. Print number 10521a
  2. Amend and recommit to health
  3. Referred to health

Companion bill

The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.

S10260Senate

Expand Newborn Disease Screening

In Senate Committee · Health · Sponsor Lea Webb

Impact 6 · Moderate28% to pass

Full text

1 pageUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗

STATE OF NEW YORK

10521--A

IN ASSEMBLY

March 6, 2026

Introduced by M. of A. HEVESI -- read once and referred to the Committee on Health -- committee discharged, bill amended, ordered reprinted as amended and recommitted to said committee

AN ACT to amend the public health law, in relation to newborn screening for CLN2, MPS IVA, MPS VI, MPS VII and Fabry diseases

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. Subdivision 1 of section 2500-a of the public health law is amended by adding five new paragraphs (l), (m), (n), (o) and (p) to read as follows:

(l) Late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2).

(m) Mucopolysaccharidosis type IVA (MPS IVA).

(n) Mucopolysaccharidosis type VI (MPS VI).

(o) Mucopolysaccharidosis type VII (MPS VII).

(p) Fabry.

§ 2. Section 2500-a of the public health law is amended by adding a new subdivision 4 to read as follows:

4. The commissioner shall ensure tests are made available for all diseases and conditions designated pursuant to paragraphs (l), (m), (n), (o) and (p) of subdivision one of this section within twelve months of the effective date of such paragraphs.

§ 3. This act shall take effect immediately.

EXPLANATION--Matter in italics (underscored) is new; matter in brackets

[ ] is old law to be omitted.

LBD15047-02-6

Reflowed for reading: line numbers and page breaks removed. Cite the official text.

Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.